Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity
Cells · 22.04.2026 · 15 (9) · 741
DOI: 10.3390/cells15090741 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 22.04.2026. Verfasst von Iseulys Richert und 6 weiteren Autor:innen. Beteiligte Einrichtung: Brenus-Pharma, 69002 Lyon, France. Hauptthemen laut MEDLINE: Haptens, Immunotherapy, Neoplasms. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hapten-based immunotherapies represent a promising strategy to enhance the immunogenicity of tumor antigens and promote antitumor immune responses. Chemical conjugation of small haptens to antigens generates novel antigenic determinants that increase immune recognition. Mechanistic studies indicate that haptenation enhances antigen uptake, dendritic cell maturation, and the activation of both cellular and humoral immunity. In preclinical models, hapten-modified antigens induce robust immune activation, tumor regression, and durable immune memory. Clinically, dinitrophenyl-modified autologous tumor cell vaccines elicit delayed-type hypersensitivity responses and clonal T-cell expansion, with evidence of clinical activity and a favorable safety profile. However, their clinical benefit remains to be confirmed in larger, randomized studies. Emerging strategies include in situ haptenation and bihaptenized or stressed hapten-modified allogeneic platforms, which aim to expand epitope diversity and enhance immune priming. Hapten-based immunotherapies offer a clinically feasible approach to converting poorly immunogenic tumors into effective immune targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brenus-Pharma, 69002 Lyon, France.
- University of Bourgogne Franche-Comté, 21000 Dijon, France.
- Department of Medical Oncology, Centre Georges-François Leclerc, 21000 Dijon, France.
- Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France.
ORCID-Profile: Paul Bravetti, François Ghiringhelli
Zitieren
APA
Richert, I., Chalus, L., Pinteur, B., Bravetti, P., Tortorelli, C., Alzeeb, G., & Ghiringhelli, F. (2026). Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity. Cells, 15(9), 741. https://doi.org/10.3390/cells15090741
Vancouver
Richert I, Chalus L, Pinteur B, Bravetti P, Tortorelli C, Alzeeb G, et al. Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity. Cells. 2026;15(9):741. doi:10.3390/cells15090741
BibTeX
@article{Richert2026,
author = {Richert, Iseulys and Chalus, Lionel and Pinteur, Benoit and Bravetti, Paul and Tortorelli, Corinne and Alzeeb, George and Ghiringhelli, François},
title = {Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity},
journal = {Cells},
year = {2026},
volume = {15},
number = {9},
pages = {741},
doi = {10.3390/cells15090741}
}
EUVIMED